Alto Neuroscience Initiates Phase 2 Study Of ALTO-101 For Cognitive Impairment Associated With Schizophrenia
Portfolio Pulse from Benzinga Newsdesk
Alto Neuroscience has initiated a Phase 2 study of ALTO-101, a treatment for cognitive impairment associated with schizophrenia.
June 20, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alto Neuroscience has begun a Phase 2 study for ALTO-101, targeting cognitive impairment in schizophrenia. This development could be significant for the company's future prospects.
The initiation of a Phase 2 study is a critical step in drug development and can lead to increased investor confidence and potential future revenue if the study is successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100